The Food and Drug Administration announced Thursday it is conducting a safety review of the asthma drug Xolair after data from an ongoing study suggested an increased number of heart attacks and strokes among patients who use it. Xolair is approved for use by adults and adolescents (12 and older) with moderate to severe persistent asthma who react to a perennial airborne allergen and whose symptoms are not well controlled with inhaled corticosteroids. "We're not getting into numbers at this point because we're still in that evaluation stage," said Genentech spokeswoman Tara Cooper. cardiac failure" and other conditions "in patients treated with Xolair compared to the control group of patients not given the drug," the agency said. The FDA did not recommend changes to the prescribing information and is not advising patients to stop taking Xolair.